Evidence map›Paper›PMID 42310485›Full record

ReviewChirality2026

Chiral (Stereoselective) Drugs, Asymmetric Synthesis, and Racemic Resolution Methods.

Burcu Karayavuz, Cigdem Karaaslan Kirmizioglu

Abstract readReview
In one paragraph

Review in Chirality, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Burcu KarayavuzFaculty of Gulhane Pharmacy, Department of Pharmaceutical Chemistry, University of Health Sciences, Ankara, Turkey.ORCID https://orcid.org/0000-0001-9631-2575
Cigdem Karaaslan KirmiziogluFaculty of Gulhane Pharmacy, Department of Pharmaceutical Chemistry, University of Health Sciences, Ankara, Turkey.ORCID https://orcid.org/0000-0003-1918-1377

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chirality is of great importance in drug development since both biological targets in the organism and the majority of pharmacologically active compounds created today are chiral. The synthesis and resolution of chiral compounds are critical steps while developing chiral drugs, as the chirality of a molecule can significantly affect its efficacy, safety (side effects and toxicity), and metabolism. While one enantiomer has therapeutic properties, the other enantiomer might be harmful, toxic, or ineffective. In recent years, the trends towards developing single enantiomer drugs have increased in the pharmaceutical industry. Various synthetic strategies and racemic resolution techniques are employed to obtain optically pure chiral drugs. Regulatory authorities also give more priority to assessing the biological efficacy of each chiral drug's enantiomer. This review summarizes the asymmetric synthesis and racemic resolution methods for producing pure enantiomeric pharmaceutical active ingredients and their synthetic intermediates, with examples from the pharmaceutical industry. By examining current approaches and challenges in the field, we aim to provide a comprehensive understanding of the processes that ensure the production of safe and effective chiral-specific drugs.

Indexed as

Chemistry Techniques, SyntheticBulk DrugsPharmaceutical PreparationsStereoisomerismBulk DrugsPharmaceutical Preparations

Identifiers

PMID42310485
PMCPMC13275641

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.